[Phenotypical plasticity and targeted therapies in non-small cell lung carcinomas].

[Phenotypical plasticity and targeted therapies in non-small cell lung carcinomas]. Rev Mal Respir. 2019 Apr 19;: Authors: Da Silva J, Dalstein V, Polette M, Nawrocki-Raby B Abstract Lung cancer is the most diagnosed and deathly type of cancer worldwide. It has a poor prognosis because of a late diagnosis, high metastatic potential and resistance to conventional therapies. Since the 2000s, the emergence of targeted therapies has improved patients' outcomes. However, these therapies concern only a small proportion of patients, selected by the presence of molecular biomarkers that indicate the targeting relevance. Here, we discuss the possibility that new phenotypical biomarkers could be predictive factors for targeted therapies in lung cancer. PMID: 31010761 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research